Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.42 |
| ▸ | DHODH | Q02127 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | ALPL | P05186 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | TTK | P33981 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.40 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5739924 | 0.85 | SMN1; SMN2 (0.53) | KDM4ELMNAATMNPSR1DHODH | |
| SCHEMBL4717637 | 0.81 | ALDH1A1 (0.53) | KDM4EATMNPSR1MAP2K4ALDH1A1 | |
| SCHEMBL5246521 | 0.79 | ATM (0.42) | KDM4ELMNAATMNPSR1MAP2K4 | |
| SCHEMBL4712870 | 0.77 | ALDH1A1 (0.45) | KDM4EATMNPSR1DHODHALDH1A1 | |
| SCHEMBL5253599 | 0.77 | ALDH1A1 (0.41) | KDM4ELMNAATMNPSR1DHODH | |
| SCHEMBL5252150 | 0.75 | MAPK1 (0.41) | KDM4ELMNAATMNPSR1DHODH | |
| SCHEMBL5739195 | 0.73 | ALDH1A1 (0.41) | KDM4EATMNPSR1ALDH1A1HPGD | |
| SCHEMBL4710883 | 0.73 | ALDH1A1 (0.41) | KDM4EATMNPSR1MAP2K4ALDH1A1 | |
| SCHEMBL10389582 | 0.71 | DHODH (0.54) | KDM4ELMNADHODHALDH1A1PDE10A | |
| SCHEMBL3186470 | 0.69 | CSNK2A2 (0.49) | KDM4ELMNAALDH1A1HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6841556-B2 | Pyrazoloisoquinoline derivatives for inhibiting NFκB-inducing kinase | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-11 | — | — | US | claimed |
| US-20040097541-A1 | Pyrazoloisoquinoline derivatives for inhibiting NFkappaB-inducing kinase | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-05-20 | — | — | US | claimed |
| WO-2004005287-A9 | PYRAZOLOISOQUINOLINE DERIVATIVES FOR INHIBITING NFKAPPAB-INDUCING KINASE (NIK) | AVENTIS PHARMA GMBH (DE) | 2004-03-04 | — | — | WO | claimed |
| EP-1644371-B1 | PYRAZOLOISOQUINOLINE DERIVATIVES AS KINASE INHIBITORS | AVENTIS PHARMA INC (US) | 2008-02-13 | — | — | EP | disclosed |
| EP-1519934-B1 | PYRAZOLOISOQUINOLINE DERIVATIVES FOR INHIBITING NF$G(K)B-INDUCING KINASE (NIK) | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-09-19 | — | — | EP | disclosed |
| US-7132428-B2 | Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2006-11-07 | — | — | US | disclosed |
| EP-1644371-A1 | PYRAZOLOISOQUINOLINE DERIVATIVES AS KINASE INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005012301-A1 | PYRAZOLOISOQUINOLINE DERIVATIVES AS KINASE INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2005-02-10 | — | — | WO | disclosed |
| US-20050009859-A1 | Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2005-01-13 | — | — | US | disclosed |
| US-6841556-B2 | Pyrazoloisoquinoline derivatives for inhibiting NFκB-inducing kinase | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-11 | — | — | US | disclosed |
| US-20040097541-A1 | Pyrazoloisoquinoline derivatives for inhibiting NFkappaB-inducing kinase | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-05-20 | — | — | US | disclosed |
| WO-2004005287-A9 | PYRAZOLOISOQUINOLINE DERIVATIVES FOR INHIBITING NFKAPPAB-INDUCING KINASE (NIK) | AVENTIS PHARMA GMBH (DE) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097541-A1 | Pyrazoloisoquinoline derivatives for inhibiting NFkappaB-inducing kinase | NFKBIA, IKBKB, IKBKG | KDM4E 2732/4885LMNA 2200/4885ATM 263/4885 |
| US-20050009859-A1 | Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders | PRKDC, MAP3K2, MAP3K20 | KDM4E 3336/4885LMNA 1662/4885ATM 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.